Menu
Not yet recruiting NCT07454681

MRI Assessment of Lung Airways in Cystic Fibrosis: Evaluate MRI's Ability to Detect Changes in Airway Structure .

— Observational Cystic Fibrosis (CF)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Advanced ultrashort echo time (UTE) MRI - Ultrashort echo time (UTE) imaging is a technique that can quickly capture the fast-decaying 1H lung signal., Multiple Breath Wash out (MBW).
Who it may be relevant to
Registry conditions: Cystic Fibrosis (CF). Basic parameters: 6 years — 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Development of Magnetic Resonance Imaging Airway Segmentation to Assess and Monitor Cystic Fibrosis Lung Disease

Overview

This study is being done to determine whether MRI can produce high quality lung and airway images in healthy and CF patients and if MRI can be used to evaluate size and shape of the airways with computer assistance. This study will also repeat MRI experiments two years after the initial MRI scan to see if changes to airway size and shape are seen over time. In a subset of participants, we will investigate whether MRI results are repeatable and reproducible in the short-term one week after the initial MRI visit. This study will help understand if MRI based measurements of airway size and shape can be used as a monitoring tool that does not use x-ray radiation in patients with CF.

Detailed description

Early CF disease in the lungs is characterized by repeated infection which can alter dimensions of the airways , especially abnormal dilation of the airways (bronchiectasis) Airway tree mapping is a form of quantitative imaging that investigates segmentation and dimensionality of the upper airways. CT detects utilized to characterize airway dimension in adults with COPD, but involves ionizing radiation. Unexplored in children.

MRI: Non-invasive, radiation-free, ideal for longitudinal monitoring. However, struggles with lung imaging due to low signal intensity, short T2 relaxation times, and motion artifacts Advanced ultrashort echo time (UTE) MRI enables high-resolution airway imaging with motion correction for free-breathing airway imaging. May permit airway tree mapping in children while obviating ionizing radiation risk.

Interventions

  • Device Advanced ultrashort echo time (UTE) MRI - Ultrashort echo time (UTE) imaging is a technique that can quickly capture the fast-decaying 1H lung signal.
    UTE lung MRI with various parameters will be done to determine optimal image quality for airway segmentation. The average scanning time for each sequence is in the order of 10 minutes.
  • Device Multiple Breath Wash out (MBW)
    Lung clearance index (LCI) will be determined by nitrogen multiple breath washout using the Exhalyzer D for measurement of inert gas washout. LCI measures will be taken in triplicate to ensure reproducibility.

Primary outcome measures

  • Airway Lumen Diameter measured by UTE MRI [Time frame: Baseline (Visit 1A); Optional 1-week repeatability visit (Visit 1B) & 2-year follow-up (Visit 2A)]
Secondary outcome measures (1)
  • Lung Clearance Index (LCI) [Time frame: Baseline (Visit 1A); Optional 1-week repeatability visit (Visit 1B) & 2-year follow-up (Visit 2A)]

Eligibility criteria

Group 1

Inclusion criteria

  • Participants must be greater than or equal to 6 years of age and not greater than 18 years of age.
  • Informed consent by patient or parent/guardian consent and participant assent when appropriate.
  • Able to perform reproducible spirometry

Exclusion criteria

  • Medical instability that would preclude the ability to undergo the required investigations
  • FEV1 % predicted < 40%
  • Severe claustrophobia
  • Does not meet MRI screening criteria
  • Usage of oral antibiotics within 3 weeks prior to study visit
  • Known pulmonary disease

Group 2 Inclusion Criteria

  • Diagnosis of CF as evidenced by one or more clinical feature consistent with the CF phenotype or positive CF newborn screen
  • Participants must be greater than or equal to 6 years of age and not greater than 18 years of age.
  • Informed consent by patient or parent/guardian consent and participant assent when appropriate.
  • Able to perform reproducible spirometry

Exclusion criteria

  • Medical instability that would preclude the ability to undergo the required investigations
  • FEV1 % predicted < 40%
  • Severe claustrophobia
  • Does not meet MRI screening criteria
  • Worsening cough and/or sputum production within the past 3 days prior to study visit
  • The use of new oral and/or inhaled antibiotics within 3 weeks prior to study visit
  • Received intravenous antibiotics within 2 weeks prior to study visit
  • The use of supplementary oxygen
  • Status of post lung or another organ transplant

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

Canada · 1 center
  • Hospital for Sick Children — Toronto

Identifiers

NCT: NCT07454681 · 1000080841 · PJT- 186007

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗